Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05869669 · ClinicalTrials.gov registry record · Phase 2
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
A Phase 2 study of Dementia With Lewy Bodies, sponsored by EIP Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 20
- Study locations
NCT05869669 is a Phase 2 study of Dementia With Lewy Bodies that has completed, run by EIP Pharma. The registered enrollment target is 159 participants, below the 464-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05869669, a Phase 2 study of Dementia With Lewy Bodies, has completed, sponsored by EIP Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Neflamapimod
Study Locations (20)
California
- UCSD Health Sciences - Movement Disorders Center - La Jolla
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Stanford Neuroscience Health Center - Palo Alto
- SC3 Research Group - Pasadena
Florida
- JEM Research Institute - Lake Worth
- ClinCloud - Melbourne
- AdventHealth Neuroscience Research - Orlando
- Panhandle Research and Medical Clinic - Pensacola
Arizona
- Barrow Neurological Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
- Banner Alzheimer's Institute - Edson Family Lewy Body Dementia Center - Tucson
Colorado
- University of Colorado - Dept of Neurology - Aurora
District of Columbia
- Georgetown Univ Hospital - Dept of Neurology - Washington D.C.
Kansas
- University of Kansas Medical Center - Kansas City
Louisiana
- Tandem Clinical Research - Marrero
Maryland
- Johns Hopkins School of Medicine - Dept of Neurology - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05869669
The ClinicalTrials.gov registry entry for NCT05869669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 464-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (66% lower). The listed sponsor is EIP Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dementia With Lewy Bodies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05869669 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05869669 about?
NCT05869669 is a clinical study titled "RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies". The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured...
What is the current status of trial NCT05869669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2023-05-01. Estimated completion is 2025-06-16.
What conditions does trial NCT05869669 study?
This clinical trial studies the following conditions: Dementia With Lewy Bodies.
What interventions are being tested in trial NCT05869669?
The interventions under investigation include: Placebo (DRUG), Neflamapimod (DRUG).
Who is sponsoring clinical trial NCT05869669?
This trial is sponsored by EIP Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05869669 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia With Lewy Bodies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
RECRUITING · Phase 2
-
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
RECRUITING · Phase 2
-
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
COMPLETED · Phase 2
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
-
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
RECRUITING · Phase 4
-
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.